DOCSLIB.ORG

Hazardous Drug Acknowledgement Statement

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hazardous Drug Acknowledgement Statement Hazardous Drug Handling Statement Hazardous Drug Acknowledgement Statement I understand that working with hazardous drugs in a pharmacy healthcare setting might cause health issues such as rashes, infertility, miscarriage, birth defects, and possibly cancer. I understand that the accidental exposure to some of these drugs might additionally cause irritation or damage to skin, eyes, or other exposed body parts. I understand that the handling of bodily fluids (urine, feces, sweat, and vomit) or bodily- fluid- contaminated clothing, dressing, linens, and other materials comes with potential exposure to hazardous drugs. I understand that the pharmacy OneWorld will follow reasonable policies and procedures in order to minimize my exposure to these drugs in accordance with commonly available information and guidance by such entities as the FDA and OSHA. I understand that the pharmacy OneWorld will also provide for safety measures and appropriate personal protective equipment to help limit my exposure to, or limit the results of, accidental exposure to such drugs. I also understand that these policies and procedures will be routinely reviewed and revised as needed in light of new information. I have been provided with training concerning hazardous drugs, and have passed a test verifying my understanding of key information concerning them. I understand that similar training will be repeated at least annually. __________________________________________ __________________________ Printed Employee Name Date __________________________________________ __________________________ Employee Signature Date USP 800 Med List for Clinic (11/20/19) Trade Name Generic Name Preparation & Disposal* Spill ** Administration Amethia, Levonorgestrel In clinic dispense: Return pill package Single use gloves Avaine, no single use back to pharmacy if Camrese gloves expired Cytotec Misoprostol Single use glove Dispose of gloves, Single use gloves med cup, and packaging Delestrogen Estradiol Single use glove Dispose of gloves, Double chemo gloves, needle, vial, & gown, & eye protection syringe Depo Provera Medroxyprogesterone Single use glove Dispose of gloves, Double chemo gloves, needle, vial, & gown, & eye protection syringe Depo Testosterone Single use glove Dispose of gloves, Double chemo gloves, Testosterone needle, vial, & gown, & eye protection syringe Ella Ulipristal In clinic dispense: Return pill package Single use gloves no single use back to pharmacy if gloves expired Femynor Norgestimate In clinic dispense: Return pill package Single use gloves no single use back to pharmacy if gloves expired Introvale, Levonorgestrel In clinic dispense: Return pill package Single use gloves Jolessa no single use back to pharmacy if gloves expired Kyleena Levonorgestrel Single use glove Disposal of Single use gloves packaging & implant Lessina Levonorgestrel In clinic dispense: Return pill package Single use gloves no single use back to pharmacy if gloves expired Liletta Levonorgestrel Single use glove Disposal of Single use gloves packaging & implant Lupron Depot Leuprolide acetate Single use glove Dispose of gloves, Single use gloves needle, vial, & syringe Lutera Levonorgestrel In clinic dispense: Return pill package Single use gloves no single use back to pharmacy if gloves expired Makena Hydroxyprogestrone Single use glove Dispose of gloves, Double chemo gloves, needle, vial, and gown, & eye protection syringe My Way Levonorgestrel In clinic dispense: Return pill package Single use gloves no single use back to pharmacy if gloves expired Nexplanon Etonogestrel Single use glove Disposal of Single use gloves packaging & implant Next Choice Levonorgestrel In clinic dispense: Return pill package Single use gloves One Dose no single use back to pharmacy if gloves expired Nuva Ring Etonogestrel In clinic dispense: Return package Single use gloves no single use back to pharmacy if gloves expired Orsythia Levonorgestrel In clinic dispense: Return pill package Single use gloves no single use back to pharmacy if gloves expired Ortho Cyclen, Norgestimate In clinic dispense: Return pill package Single use gloves Ortho Tri no single use back to pharmacy if Cylen (Lo) gloves expired Ortho Evra Xulane In clinic dispense: Return package Single use gloves no single use back to pharmacy if gloves expired Ortho‐ Norethindrone In clinic dispense: Return pill package Single use gloves Micronor no single use back to pharmacy if gloves expired Plan B Levonorgestrel In clinic dispense: Return pill package Single use gloves no single use back to pharmacy if gloves expired Previfem Norgestimate In clinic dispense: Return pill package Single use gloves no single use back to pharmacy if gloves expired Saxenda Liraglutide Single use glove Dispose of needle. Single use gloves Dispose of pen when empty (Lo) Levonorgestrel In clinic dispense: Return pill package Single use gloves Seasonique no single use back to pharmacy if gloves expired Skyla Levonorgestrel Single use glove Dispose of Single use gloves packaging, & implant Sprintec, Norgestimate In clinic dispense: Return pill package Single use gloves Trinessa, no single use back to pharmacy if Tri Lo Marzia, gloves expired Tri‐(Lo) Sprintec Trexall Methotrexate Single use chemo Dispose of gloves, Double chemo gloves, gloves needle, vial, & gown, and eye syringe protection Victoza Liraglutide Single use glove Dispose of needle. Single use gloves Dispose of pen when empty Xultophy Insulin degludec + Single use glove Dispose of needle. Single use gloves liraglutide Dispose of pen when empty *Disposal – all equipment in YELLOW hazardous drug container(s) marked Trace Hazardous Drugs **Spill – all used equipment/PPE in RED biohazardous tote in biohazard room *** Chemo gloves‐ Nitrile Exam Gloves Powder Free (blue) USP800 Training: Handling and Disposal Objectives • Review current USP800 guidelines on hazardous medications for safe handling of hazardous drugs to minimize risk of exposure to healthcare personnel, patients, and environment. • Illustrate how clinic demonstrates compliance with USP800 guidelines involving hazardous medication administration & disposal. USP800 – What is it? • The USP chapter that contains guidelines for hazardous drug handling, administration, and disposal. • Since it is below 1000 in the USP chapters it is enforceable by regulatory bodies. • Joint Commission will be surveying for compliance. • Implementation date of December 1, 2019. Who does USP800 affect? • Healthcare settings to include pharmacies, physician offices, clinics, veterinary offices, and other locations that handle hazardous drugs. • The word “entity” in USP800 means your setting if you are handling hazardous medications What medications make “the list”? • NIOSH list of antineoplastic and other hazardous drugs in USP800 that pose hazard to health care workers. ▫ Carcinogens, Teratogens, Reproductive toxicity, Organ toxicity, Genotoxicity, Chemical structure and toxicity that mimic existing drugs that are hazardous Drugs found in the clinic that are on USP800 list (see risk assessment list- this is kept in the Y drive under Nursing??): Methotrexate, all forms of birth control, medication with any type of hormonal component (to include any traces of these medications) Containment strategies for USP800 • Engineering controls • Personal Protective Equipment • Work Practices Work Practices for USP800 • Disposal: Section 11 of USP800 • The entity must establish SOP’s for the labeling, packaging, transport, and disposal of HD’s. • 11.4 Disposal: ….Disposal of all HD waste, including, but not limited to, unused HD’s and trace-contaminated PPE and other materials, must comply with all applicable federal, state, and local regulation. Transportation of HD Pharmacy will place hazardous drug in plastic zip bag (Depo Provera, depo testosterone) or appropriate container indicating contents are hazardous drugs. This excludes items that are already commercially packaged and ready for patient use (ex: birth control pills, patches, rings, IUDs, and any creams or ointments). Disposal – What determines the proper disposal method for a medication? • RCRA (Resource Conservation and Recovery Act) ▫ P-listed – Warfarin, Arsenic, Nicotine ▫ U-listed – all in this category are toxic. Mitomycin, Mercury • NIOSH (National Institute of Occupational Safety and Health) ▫ A part of the CDC ▫ A list of hazardous medications is published and risk categories are assigned. • OSHA (Occupational Safety and Health Administration) ▫ An agency of the US Department of Labor ▫ Responsible for providing a safe and healthful workplace Who regulates and enforces proper medication disposal? • The Resource Conservation and Recovery Act (RCRA) gives EPA the authority to control hazardous waste from the "cradle-to-grave." This includes the generation, transportation, treatment, storage, and disposal of hazardous waste. • NIOSH and CDC may not be actual federal regulations but can be incorporated in state or local law or hospital policies • Joint Commission considers proper disposal of hazardous medication waste as part of their Environment of Care standards • FDA gives guidance • State and federal government can enforce USP Hazardous Medication Waste Trace waste ▫Empty syringes or vials that contained any hazardous medication; and/or gloves used in preparation, administration or clean up. ▫Must be discarded in a YELLOW hazardous waste bin (McKesson stocks these) Yellow Hazardous Waste Bin Chemo Gloves PPE Disposal *Any gowns, masks, goggles, and gloves may be disposed of in the red biohazard
Load more

Recommended publications
  • Specialty Drug List 10-22-12 Final
    Iowa Medicaid Specialty Drug List Effective 10/22/2012 “Specialty” drugs include biological drugs, blood-derived products, complex molecules, and select oral, injectable, and infused medications identified by the Department and reimbursed at AWP-17% plus the dispensing fee. Specialty pricing will be applied to both the brand and generic drug products. NOTE: See the PDL at www.iowamedicaidpdl.com for specific PA criteria for the following drugs. BRAND NAME GENERIC NAME AGENTS FOR GAUCHER DISEASE ELELYSO taliglucerase alfa VPRIV velaglucerase alfa ALS RILUTEK riluzole ALCOHOL DEPENDENCE VIVITROL naltrexone AMINOGLYCOSIDES TOBI tobramycin ANTI-ASTHMATICS ALPHA PROTEINASE INHIBITORS ARALAST proteinase inhibitor ARALAST NP proteinase inhibitor PROLASTIN, C proteinase inhibitor ZEMAIRA alpha-1 proteinase inhibitor ANTIASTHMATIC - BETA - ADRENERGICS BRETHINE INJECTION turbutaline sulfate ANTIASTHMATIC - HYDRO-LYTIC ENZYMES KALYDECO ivacaftor ANTIBIOTICS - MISC. CAYSTON aztreonam lysine for inhal soln ANTI-CATAPLECTIC AGENTS XYREM sodium oxybate oral solution ANTICOAGULANTS ARIXTRA fondaparinux sodium FRAGMIN dalteparin sodium INNOHEP tinzaparin sodium LOVENOX enoxaparin sodium ANTICONVULSANTS SABRIL vigabatrin ANTIDOTES FERRIPROX deferiprone ANTIDOTES - CHELATING AGENTS CHEMET succimer EXJADE deferasirox tab for oral susp Page 1 of 10 ANTIEMETIC - TETRAHYDROCANNABINOL (THC) DERIVATIVES MARINOL dronabinol ANTIFUNGALS - ASSORTED AMBISOME amphotericin B Liposome IV for suspension ANCOBON flucytosine CANCIDAS caspofungin acetate for IV solution
    [Show full text]
  • Ocps) Used in the NM Family Planning Program (FPP
    The following slides are intended to familiarize nurses and clinicians with oral contraceptive pills (OCPs) used in the NM Family Planning Program (FPP). The FPP does not intend for this information to supersede the Family Planning Protocol particularly on the requirement for Public Health Nurses in the Public Health Offices to consult a clinician as stated in the Protocol when in doubt or if it is necessary to switch the client’s OCP type. 1 2 Combined oral contraceptives (COCs) contain two hormones; estrogen and progestin. In general, any combined OCP is good for most women who are eligible to take estrogen according to the CDC U.S. Medical Eligibility Criteria (MEC). Once again, refer to the US MEC chart to find out if OCP is a suitable choice for clients with specific health conditions. To learn a little bit about what each hormone does, the FPP is providing the following summary: Estrogen: provides endometrial stability = menstrual cycle control. A higher estrogen dose increases the venous thromboembolism (VTE) or clot risk but OCP clot risk is still less harmful than the clot risk related to pregnancy and giving birth. Progestin: provides most of the contraceptive effect by ‐Preventing luteinizing hormone (LH) surge /ovulation ‐Thickening the cervical mucus to prevent sperm entry. Two major OCP formations are available. Monophasic: There is only one dose of estrogen and progestin in each active pill in the packet; and Multiphasic: There are varying doses of hormones, particularly progestin in the active pills. 3 Section 3 of the FPP Protocol contains the OCP Substitute Table, which groups OCPs into 6 classes according to the estrogen dosage, the type of progestin and the formulations.
    [Show full text]
  • Aromasin (Exemestane)
    HIGHLIGHTS OF PRESCRIBING INFORMATION ------------------------------ADVERSE REACTIONS------------------------------­ These highlights do not include all the information needed to use • Early breast cancer: Adverse reactions occurring in ≥10% of patients in AROMASIN safely and effectively. See full prescribing information for any treatment group (AROMASIN vs. tamoxifen) were hot flushes AROMASIN. (21.2% vs. 19.9%), fatigue (16.1% vs. 14.7%), arthralgia (14.6% vs. 8.6%), headache (13.1% vs. 10.8%), insomnia (12.4% vs. 8.9%), and AROMASIN® (exemestane) tablets, for oral use increased sweating (11.8% vs. 10.4%). Discontinuation rates due to AEs Initial U.S. Approval: 1999 were similar between AROMASIN and tamoxifen (6.3% vs. 5.1%). Incidences of cardiac ischemic events (myocardial infarction, angina, ----------------------------INDICATIONS AND USAGE--------------------------- and myocardial ischemia) were AROMASIN 1.6%, tamoxifen 0.6%. AROMASIN is an aromatase inhibitor indicated for: Incidence of cardiac failure: AROMASIN 0.4%, tamoxifen 0.3% (6, • adjuvant treatment of postmenopausal women with estrogen-receptor 6.1). positive early breast cancer who have received two to three years of • Advanced breast cancer: Most common adverse reactions were mild to tamoxifen and are switched to AROMASIN for completion of a total of moderate and included hot flushes (13% vs. 5%), nausea (9% vs. 5%), five consecutive years of adjuvant hormonal therapy (14.1). fatigue (8% vs. 10%), increased sweating (4% vs. 8%), and increased • treatment of advanced breast cancer in postmenopausal women whose appetite (3% vs. 6%) for AROMASIN and megestrol acetate, disease has progressed following tamoxifen therapy (14.2). respectively (6, 6.1). ----------------------DOSAGE AND ADMINISTRATION----------------------- To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc at Recommended Dose: One 25 mg tablet once daily after a meal (2.1).
    [Show full text]
  • Assessment of Overall Survival, Quality of Life, And
    Supplementary Online Content Salas-Vega S, Iliopoulos O, Mossialos E. Assesment of overall survival, quality of life, and safety benefits associated with new cancer medicines [published online December 29, 2016]. JAMA Oncol. doi:10.1001/jamaoncol.2016.4166 eTable 1. Therapeutic profile of all cancer medicines approved by the FDA between 2003- 2013 eTable 2. Regulatory evidence in support of classification of drug clinical benefits eFigure 1. Number of cancer drugs that were evaluated by all three HTA agencies, sorted by magnitude of clinical benefits eTable 3. Interagency agreement–Krippendorff’s alpha coefficients eMethods This supplementary material has been provided by the authors to give readers additional information about their work. Online-Only Supplement © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/25/2021 Clinical value of cancer medicines Contents eExhibits ......................................................................................................................................................... 3 eTable 1. Therapeutic profile of all cancer medicines approved by the FDA between 2003- 2013 (Summary of eTable 2) ................................................................................................................... 3 eTable 2. Regulatory evidence in support of classification of drug clinical benefits ....................... 6 eFigure 1. Number of cancer drugs that were evaluated by all three HTA agencies, sorted by magnitude of clinical benefits
    [Show full text]
  • The Chemotherapy of Malignant Disease -Practical and Experimental Considerations
    Postgrad Med J: first published as 10.1136/pgmj.41.475.268 on 1 May 1965. Downloaded from POSTGRAD. MED. J. (1965), 41,268 THE CHEMOTHERAPY OF MALIGNANT DISEASE -PRACTICAL AND EXPERIMENTAL CONSIDERATIONS JOHN MATTHIAS, M.D., M.R.C.P., F.F.A., R.C.S. Physician, The Royal Marsden Hospital, London, S.W.3. THE TERM chemotherapy was introduced by positively charged alkyl (CH2) radicles of Ehrlich to describe the specific and effective the agent. treatment of infectious disease by chemical (a) The nitrogen mustards: mustine (HN2 substances. It is currently also applied to the 'nitrogen mustard', mechlorethamine, treatment of malignant disease. Unfortunately mustargen), trimustine (Trillekamin no aspect of tumour metabolism has been HN3), chlorambucil (Leukeran, phenyl discovered which has allowed the development butyric mustard), melphalan (Alkeran, of drugs capable of acting specifically upon the phenyl alanine mustard), uramustine malignant cell, so that cytotoxic drugs also (Uracil mustard), cyclophosphamide affect normal cells to a greater or lesser degree. (Endoxan or Cytoxan), mannomustine The most susceptible or sensitive of the normal (DegranoO). tissues are those with the highest rates of cell (b) The ethylenamines: tretamine (trie- turnover and include the haemopoietic and thanomelamine, triethylene melamine, lympho-reticular tissues, the gastro-intestinal TEM), thiotepa (triethylene thiopho- the the testis and the hair epithelium, ovary, sphoramide), triaziquone (Trenimon).by copyright. follicles. (c) The epoxides: triethyleneglycoldigly- Cancer chemotherapy may be said to encom- cidyl ether (Epodyl). pass all treatments of a chemical nature (d) The sulphonic acid esters: busulphan administered to patients with the purpose of (Myleran), mannitol myleran. restricting tumour growth or destroying tumour 2.
    [Show full text]
  • Comparing the Effects of Combined Oral Contraceptives Containing Progestins with Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis In
    JMIR RESEARCH PROTOCOLS Amiri et al Review Comparing the Effects of Combined Oral Contraceptives Containing Progestins With Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis in Patients With Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis Mina Amiri1,2, PhD, Postdoc; Fahimeh Ramezani Tehrani2, MD; Fatemeh Nahidi3, PhD; Ali Kabir4, MD, MPH, PhD; Fereidoun Azizi5, MD 1Students Research Committee, School of Nursing and Midwifery, Department of Midwifery and Reproductive Health, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 2Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 3School of Nursing and Midwifery, Department of Midwifery and Reproductive Health, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 4Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Islamic Republic Of Iran 5Endocrine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran Corresponding Author: Fahimeh Ramezani Tehrani, MD Reproductive Endocrinology Research Center Research Institute for Endocrine Sciences Shahid Beheshti University of Medical Sciences 24 Parvaneh Yaman Street, Velenjak, PO Box 19395-4763 Tehran, 1985717413 Islamic Republic Of Iran Phone: 98 21 22432500 Email: [email protected] Abstract Background: Different products of combined oral contraceptives (COCs) can improve clinical and biochemical findings in patients with polycystic ovary syndrome (PCOS) through suppression of the hypothalamic-pituitary-gonadal (HPG) axis. Objective: This systematic review and meta-analysis aimed to compare the effects of COCs containing progestins with low androgenic and antiandrogenic activities on the HPG axis in patients with PCOS.
    [Show full text]
  • PMBJP Product.Pdf
    Sr. Drug Generic Name of the Medicine Unit Size MRP Therapeutic Category No. Code Analgesic & Antipyretic / Muscle 1 1 Aceclofenac 100mg and Paracetamol 325 mg Tablet 10's 10's 8.00 relaxants Analgesic & Antipyretic / Muscle 2 2 Aceclofenac Tablets IP 100mg 10's 10's 4.37 relaxants Acetaminophen 325 + Tramadol Hydrochloride 37.5 film Analgesic & Antipyretic / Muscle 3 4 10's 8.00 coated Tablet 10's relaxants Analgesic & Antipyretic / Muscle 4 5 ASPIRIN Tablets IP 150 mg 14's 14's 2.70 relaxants DICLOFENAC 50 mg+ PARACETAMOL 325 mg+ Analgesic & Antipyretic / Muscle 5 6 10's 11.30 CHLORZOXAZONE 500 mg Tablets 10's relaxants Diclofenac Sodium 50mg + Serratiopeptidase 10mg Tablet Analgesic & Antipyretic / Muscle 6 8 10's 12.00 10's relaxants Analgesic & Antipyretic / Muscle 7 9 Diclofenac Sodium (SR) 100 mg Tablet 10's 10's 6.12 relaxants Analgesic & Antipyretic / Muscle 8 10 Diclofenac Sodium 25mg per ml Inj. IP 3 ml 3 ml 2.00 relaxants Analgesic & Antipyretic / Muscle 9 11 Diclofenac Sodium 50 mg Tablet 10's 10's 2.90 relaxants Analgesic & Antipyretic / Muscle 10 12 Etoricoxilb Tablets IP 120mg 10's 10's 33.00 relaxants Analgesic & Antipyretic / Muscle 11 13 Etoricoxilb Tablets IP 90mg 10's 10's 25.00 relaxants Analgesic & Antipyretic / Muscle 12 14 Ibuprofen 400 mg + Paracetamol 325 mg Tablet 10's 15's 5.50 relaxants Analgesic & Antipyretic / Muscle 13 15 Ibuprofen 200 mg film coated Tablet 10's 10's 1.80 relaxants Analgesic & Antipyretic / Muscle 14 16 Ibuprofen 400 mg film coated Tablet 10's 15's 3.50 relaxants Analgesic & Antipyretic
    [Show full text]
  • ORTHO TRI-CYCLEN® TABLETS ORTHO-CYCLEN® TABLETS (Norgestimate/Ethinyl Estradiol)
    PHYSICIANS' PACKAGE INSERT ORTHO TRI-CYCLEN® TABLETS ORTHO-CYCLEN® TABLETS (norgestimate/ethinyl estradiol) Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases. DESCRIPTION Each of the following products is a combination oral contraceptive containing the progestational compound norgestimate and the estrogenic compound ethinyl estradiol. ORTHO TRI-CYCLEN 21 Tablets and ORTHO TRI-CYCLEN 28 Tablets. Each white tablet contains 0.180 mg of the progestational compound, norgestimate (18,19-Dinor- 17-pregn-4-en-20-yn-3-one,17-(acetyloxy)-13-ethyl-, oxime,(17α)-(+)-) and 0.035 mg of the estrogenic compound, ethinyl estradiol (19-nor-17α-pregna,1,3,5(10)-trien-20-yne-3,17-diol). Inactive ingredients include lactose, magnesium stearate, and pregelatinized starch. Each light blue tablet contains 0.215 mg of the progestational compound norgestimate (18,19- Dinor-17-pregn-4-en-20-yn-3-one,17-(acetyloxy)-13-ethyl-,oxime,(17α)-(+)-) and 0.035 mg of the estrogenic compound, ethinyl estradiol (19-nor-17α-pregna,1,3,5(10)-trien-20-yne-3,17-diol). Inactive ingredients include FD & C Blue No. 2 Aluminum Lake, lactose, magnesium stearate, and pregelatinized starch. Each blue tablet contains 0.250 mg of the progestational compound norgestimate (18,19-Dinor-17- pregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-,oxime,(17α)-(+)-) and 0.035 mg of the estrogenic compound, ethinyl estradiol (19-nor-17α-pregna,1,3,5(10)-trien-20-yne-3,17-diol). Inactive ingredients include FD & C Blue No. 2 Aluminum Lake, lactose, magnesium stearate, and pregelatinized starch.
    [Show full text]
  • Palifermin (Kepivance™) in the Treatment of Mucositis
    Session V • From cell biology to cell therapy Palifermin (Kepivance™) in the treatment of mucositis [haematologica reports] 2005;1(8):41-45 EMMANOUILIDES C n patients undergoing high dose chemo- factor (KGF) is a 28 kD member of the therapy and hematopoietic stem cell fibroblast growth factor family with epithe- Associate Profesor transplant, oral mucositis (OM) is one of lial cell proliferative properties.26 Palifermin of Medicine, UCLA, I Division Haematology-Oncology, the most debilitating and annoying side (Kepivance™) is a truncated, recombinant Thessaloniki, Greece effects. This complication results from form of human keratinocyte growth factor cytotoxic injury to the epithelial lining of (rHuKGF) that has been approved in the the oropharyngeal mucosa, although USA in 2004 to decrease the incidence and lesions of the whole gastrointestinal tract duration of severe OM in patients with also occur.1 The severity of OM varies from hematologic malignancies receiving myelo- erythema and edema accompanied by mild toxic therapy requiring HSCT support. Pal- soreness to full mucosal thickness ulcera- ifermin (recombinant human keratinocyte tions penetrating into the submucosa, growth factor) is an N-terminal, truncated often resulting in severe pain requiring version of endogenous keratinocyte growth narcotic analgesia and impaired swallow- factor with biologic activity similar to that ing, prolonged hospitalization, and of the native protein, but with increased increased risks for infections and poten- stability 26 In animal models of chemother- tially life-threatening sequelae.2,3 Between apy, radiotherapy, and hematopoietic stem- 40% to 80% of cancer patients undergo- cell transplantation27,28 palifermin protected ing intensive treatment regimens requiring several types of epithelial tissues.
    [Show full text]
  • Interactions with PBC Agents
    www.hep-druginteractions.org Interactions with PBC Agents Charts created March 2020. Full information available at www.hep-druginteractions.org Page 1 of 4 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. Obeticholic Ursodeoxycholic Obeticholic Ursodeoxycholic Obeticholic Ursodeoxycholic Acid Acid Acid Acid Acid Acid Anaesthetics & Muscle Relaxants Antibacterials (continued) Antidepressants Bupivacaine Cloxacillin Agomelatine Cisatracurium Dapsone Amitriptyline Isoflurane Delamanid Bupropion Ketamine Ertapenem Citalopram Nitrous oxide Erythromycin Clomipramine Propofol Ethambutol Desipramine Thiopental Flucloxacillin Desvenlafaxine Tizanidine Gentamicin Dosulepin Analgesics Imipenem Doxepin Aceclofenac Isoniazid Duloxetine Alfentanil Escitalopram Aspirin Levofloxacin Linezolid Fluoxetine Buprenorphine Fluvoxamine Lymecycline distribution. Celecoxib Imipramine Meropenem Codeine Lithium Methenamine Dexketoprofen Maprotiline Metronidazole Dextropropoxyphene Mianserin Moxifloxacin Diamorphine Milnacipran Diclofenac Nitrofurantoin only. Not for distribution. for only. Not Mirtazapine Diflunisal Norfloxacin Moclobemide Dihydrocodeine Ofloxacin Nefazodone Etoricoxib Penicillin V Nortriptyline Fentanyl Piperacillin Paroxetine Flurbiprofen Pivmecillinam Sertraline Hydrocodone use ersonal Pyrazinamide Tianeptine Hydromorphone Rifabutin Trazodone Ibuprofen Rifampicin
    [Show full text]
  • 4 Supplementary File
    Supplemental Material for High-throughput screening discovers anti-fibrotic properties of Haloperidol by hindering myofibroblast activation Michael Rehman1, Simone Vodret1, Luca Braga2, Corrado Guarnaccia3, Fulvio Celsi4, Giulia Rossetti5, Valentina Martinelli2, Tiziana Battini1, Carlin Long2, Kristina Vukusic1, Tea Kocijan1, Chiara Collesi2,6, Nadja Ring1, Natasa Skoko3, Mauro Giacca2,6, Giannino Del Sal7,8, Marco Confalonieri6, Marcello Raspa9, Alessandro Marcello10, Michael P. Myers11, Sergio Crovella3, Paolo Carloni5, Serena Zacchigna1,6 1Cardiovascular Biology, 2Molecular Medicine, 3Biotechnology Development, 10Molecular Virology, and 11Protein Networks Laboratories, International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 34149, Trieste, Italy 4Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy 5Computational Biomedicine Section, Institute of Advanced Simulation IAS-5 and Institute of Neuroscience and Medicine INM-9, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany 6Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy 7National Laboratory CIB, Area Science Park Padriciano, Trieste, 34149, Italy 8Department of Life Sciences, University of Trieste, Trieste, 34127, Italy 9Consiglio Nazionale delle Ricerche (IBCN), CNR-Campus International Development (EMMA- INFRAFRONTIER-IMPC), Rome, Italy This PDF file includes: Supplementary Methods Supplementary References Supplementary Figures with legends 1 – 18 Supplementary Tables with legends 1 – 5 Supplementary Movie legends 1, 2 Supplementary Methods Cell culture Primary murine fibroblasts were isolated from skin, lung, kidney and hearts of adult CD1, C57BL/6 or aSMA-RFP/COLL-EGFP mice (1) by mechanical and enzymatic tissue digestion. Briefly, tissue was chopped in small chunks that were digested using a mixture of enzymes (Miltenyi Biotec, 130- 098-305) for 1 hour at 37°C with mechanical dissociation followed by filtration through a 70 µm cell strainer and centrifugation.
    [Show full text]
  • Estrogen and Progestin Hormone Doses in Combined Birth Control Pills
    Estrogen and Progestin Hormone Doses in Combined Birth Control Pills Estrogen level Pill Brand Name Progestin Dose (mg) ethinyl estradiol (micrograms) 20 mcgm Alesse® levonorgestrel 0.10 Levlite® levonorgestrel 0.10 Loestrin 1/20® Fe norethindrone 1.00 acetate Mircette® desogestrel 0.15 Ortho Evra® norelgestromin 0.15 (patch) (norgestimate metabolite) phasic Estrostep® Fe norethindrone 1.0/1.0/1.0 20/30/35 mcgm acetate 30 mcgm Levlen® levonorgestrel 0.15 Levora® levonorgestrel 0.15 Nordette® levonorgestrel 0.15 Lo/Ovral® norgestrel 0.30 Desogen® desogestrel 0.15 Ortho-Cept® desogestrel 0.15 Loestrin® 1.5/30 norethindrone 1.50 acetate Yasmin® drospirenone 3.0 phasic Triphasil® levonorgestrel 0.05/0.075/0.125 30/40/30 mcgm Tri-Levlen® levonorgestrel 0.05/0.075/0.125 Trivora® levonorgestrel 0.05/0.075/0.125 35 mcgm Ortho-Cyclen® norgestimate 0.25 Ovcon-35® norethindrone 0.40 Brevicon® norethindrone 0.50 Modicon® norethindrone 0.50 Necon® norethindrone 1.00 Norethin® norethindrone 1.00 Norinyl® 1/35 norethindrone 1.00 Ortho-Novum® 1/35 norethindrone 1.00 Demulen® 1/35 ethynodiol diacetate 1.00 Zovia® 1/35E ethynodiol diacetate 1.00 phasic Ortho-Novum® norethindrone 0.50/1.00 35/35 mcgm 10/11 Jenest® norethindrone 0.50/1.00 phasic Ortho-Tri-Cyclen® norgestimate 0.15/0.215/0.25 35/35/35 mcgm Ortho-Novum® norethindrone 0.50/0.75/1.00 7/7/7 Tri-Norinyl® norethindrone 0.50/1.00/0.50 50 mcgm Necon® 1/50 norethindrone 1.00 Norinyl® 1/50 norethindrone 1.00 Ortho-Novum® 1/50 norethindrone 1.00 Ovcon-50® norethindrone 1.00 Ovral® norgestrel 0.50 Demulen® 1/50 ethynodiol diacetate 1.00 Zovia® 1/50E ethynodiol diacetate 1.00 Which pills have higher progestin side efects or cause more acne and hair growth? Each progestin has a diferent potency, milligram per milligram, in terms of progesterone efect to stop menstrual bleeding or androgen efect to stimulate acne and hair growth.
    [Show full text]